
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
Publication
, Journal Article
Jiang, SW; Kwock, JT; Liu, B; Petty, AJ; Zhao, AT; Green, CL; Jaleel, T
Published in: Br J Dermatol
September 2022
In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Br J Dermatol
DOI
EISSN
1365-2133
Publication Date
September 2022
Volume
187
Issue
3
Start / End Page
417 / 419
Location
England
Related Subject Headings
- Ustekinumab
- Infliximab
- Humans
- Hidradenitis Suppurativa
- Dermatology & Venereal Diseases
- Dermatologic Agents
- Adalimumab
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jiang, S. W., Kwock, J. T., Liu, B., Petty, A. J., Zhao, A. T., Green, C. L., & Jaleel, T. (2022). High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol, 187(3), 417–419. https://doi.org/10.1111/bjd.21066
Jiang, Simon W., Jeffery T. Kwock, Beiyu Liu, Amy J. Petty, Aaron T. Zhao, Cynthia L. Green, and Tarannum Jaleel. “High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.” Br J Dermatol 187, no. 3 (September 2022): 417–19. https://doi.org/10.1111/bjd.21066.
Jiang SW, Kwock JT, Liu B, Petty AJ, Zhao AT, Green CL, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022 Sep;187(3):417–9.
Jiang, Simon W., et al. “High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.” Br J Dermatol, vol. 187, no. 3, Sept. 2022, pp. 417–19. Pubmed, doi:10.1111/bjd.21066.
Jiang SW, Kwock JT, Liu B, Petty AJ, Zhao AT, Green CL, Jaleel T. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022 Sep;187(3):417–419.

Published In
Br J Dermatol
DOI
EISSN
1365-2133
Publication Date
September 2022
Volume
187
Issue
3
Start / End Page
417 / 419
Location
England
Related Subject Headings
- Ustekinumab
- Infliximab
- Humans
- Hidradenitis Suppurativa
- Dermatology & Venereal Diseases
- Dermatologic Agents
- Adalimumab
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences